NEOADJUVANT CAMRELIZUMAB IN COMBINATION WITH ALBUMIN PACLITAXEL AND CISPLATIN FOR PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
第一作者机构：[1]The Fourth Hospital of Hebei Medical University, shijiazhuang, China
推荐引用方式(GB/T 7714)：
Lv Huilai,Tian Yang,Li Zhenhua,et al.NEOADJUVANT CAMRELIZUMAB IN COMBINATION WITH ALBUMIN PACLITAXEL AND CISPLATIN FOR PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)[J].JOURNAL FOR IMMUNOTHERAPY OF CANCER.2021,9:A587-A587.doi:10.1136/jitc-2021-SITC2021.557.
APA：
Lv, Huilai,Tian, Yang,Li, Zhenhua,Huang, Chao,Xu, Yanzhao&Tian, Ziqiang.(2021).NEOADJUVANT CAMRELIZUMAB IN COMBINATION WITH ALBUMIN PACLITAXEL AND CISPLATIN FOR PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC).JOURNAL FOR IMMUNOTHERAPY OF CANCER,9,
MLA：
Lv, Huilai,et al."NEOADJUVANT CAMRELIZUMAB IN COMBINATION WITH ALBUMIN PACLITAXEL AND CISPLATIN FOR PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)".JOURNAL FOR IMMUNOTHERAPY OF CANCER 9.(2021):A587-A587
医学